Talac R, Nelson H
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota 55902, USA.
J Biol Regul Homeost Agents. 2000 Jul-Sep;14(3):175-81.
The field of bispecific antibodies is an evolving field of research that has increasing clinical appeal. The fusion of two antibodies or antibody fragments introduced a new way to override natural specificity of T cell and induce effector responses against tumor targets in MHC-unrestricted manner. Initial experiences with bispecific antibodies demonstrate both the promise for and limitations of this anti-cancer strategy. Significant body of work has shown that bispecific antibodies have potential to induce T cell mediated anti-tumor responses in pre-clinical models. However, immunotherapy with bispecific antibodies in humans has yet to prove its value in clinical settings. In addition, the production of high-quality bispecific antibodies for clinical applications, the optimal size and avidity of bispecific antibodies, and in vivo T cell pre-activation remain critical issues. In this review, we summarize recent progress in bispecific antibody-based immunotherapy and address essential aspects of this anti-cancer strategy.
双特异性抗体领域是一个不断发展的研究领域，其临床吸引力与日俱增。两种抗体或抗体片段的融合引入了一种新方法，可突破T细胞的天然特异性，并以MHC非限制性方式诱导针对肿瘤靶点的效应反应。双特异性抗体的初步经验既显示了这种抗癌策略的前景，也表明了其局限性。大量研究表明，双特异性抗体在临床前模型中具有诱导T细胞介导的抗肿瘤反应的潜力。然而，双特异性抗体在人体中的免疫治疗尚未在临床环境中证明其价值。此外，用于临床应用的高质量双特异性抗体的生产、双特异性抗体的最佳大小和亲和力以及体内T细胞预激活仍然是关键问题。在本综述中，我们总结了基于双特异性抗体的免疫治疗的最新进展，并探讨了这种抗癌策略的重要方面。
